GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Grifols SA (WBO:GRF) » Definitions » Debt-to-EBITDA
中文

Grifols (WBO:GRF) Debt-to-EBITDA : 12.88 (As of Dec. 2023)


View and export this data going back to 2017. Start your Free Trial

What is Grifols Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

Grifols's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was €898 Mil. Grifols's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was €9,220 Mil. Grifols's annualized EBITDA for the quarter that ended in Dec. 2023 was €786 Mil. Grifols's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2023 was 12.88.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Grifols's Debt-to-EBITDA or its related term are showing as below:

WBO:GRF' s Debt-to-EBITDA Range Over the Past 10 Years
Min: 0.01   Med: 4.89   Max: 14.46
Current: 14.46

During the past 13 years, the highest Debt-to-EBITDA Ratio of Grifols was 14.46. The lowest was 0.01. And the median was 4.89.

WBO:GRF's Debt-to-EBITDA is ranked worse than
95.61% of 660 companies
in the Drug Manufacturers industry
Industry Median: 1.67 vs WBO:GRF: 14.46

Grifols Debt-to-EBITDA Historical Data

The historical data trend for Grifols's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Grifols Debt-to-EBITDA Chart

Grifols Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Debt-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only 4.92 4.86 9.88 8.03 8.56

Grifols Quarterly Data
Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Dec21 Jun22 Sep22 Dec22 Jun23 Sep23 Dec23
Debt-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - 13.71 10.81 11.03 12.88

Competitive Comparison of Grifols's Debt-to-EBITDA

For the Drug Manufacturers - General subindustry, Grifols's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Grifols's Debt-to-EBITDA Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Grifols's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Grifols's Debt-to-EBITDA falls into.



Grifols Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Grifols's Debt-to-EBITDA for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(897.915 + 9219.524) / 1181.996
=8.56

Grifols's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(897.915 + 9219.524) / 785.564
=12.88

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Dec. 2023) EBITDA data.


Grifols  (WBO:GRF) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.


Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.


Grifols Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Grifols's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Grifols (WBO:GRF) Business Description

Address
Avinguda de la Generalitat, 152-158, Parc de Negocis Can Sant Joan, Sant Cugat del Valles, Barcelona, ESP, 08174
As a vertically integrated plasma derivative producer, Spain-based Grifols collects plasma and then manufactures and sells plasma-derived products globally. By acquiring Talecris in 2011, Grifols dramatically expanded its plasma-derived product portfolio, and the firm's biopharma business contributed 83% of sales in 2022. Grifols also has smaller segments including diagnostics and biosupplies. Diagnostics is roughly 10% of revenue following the Biotest acquisition.